Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 3-7 , January 2008

Antiplatelet therapy for recurrent stroke prevention: newer perspectives based on (MATCH), (CHARISMA), and (ESPRIT)

This invited Review is based on Dr. Gorelick’s presentation at a symposium held at the American Society of Hypertension Annual Meeting, in Chicago, Illinois, May 21, 2007.

  • Philip B. Gorelick, MD, MPH

      Affiliations

    • Dr. Gorelick receives honoraria as a steering committee member for studies for Bayer and Boehringer Ingelheim companies, and as a speaker for Boehringer Ingelheim.
    • Corresponding Author InformationCorresponding author: Philip B. Gorelick, MD, MPH, Center for Stroke Research, Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, 912 S. Wood Street Room 855N, Chicago, Illinois 60612. Tel: 312-996-1757; fax: 312-413-1388.

Received 25 June 2007 ,Accepted 24 July 2007.

References 

  1. Gorelick PB. Life after ESPRIT: which first–line antiplatelet agent should we use?. International Journal of Stroke. 2007;2:40–42
  2. Gorelick PB. Use of antiplatelet agents for the prevention of first and recurrent stroke. Continuum. 2005;11:77–96
  3. Gorelick PB. North American perspective of antiplatelet agents. In:  Barnett HJM,  Bogousslavsky J,  Meldrum H editor. Advances in neurology, Volume 92: ischemic stroke. Philadelphia: Lippincott, Williams & Wilkins; 2003;p. 281–291
  4. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. American Heart Association American Stroke Association Council on Stroke Council on Cardiovascular Radiology and Intervention American Academy of Neurology Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co–sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577–617
  5. Albers GW, Amarenco P, Easton DJ, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke (The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy). Chest. 2004;126:483S–512S
  6. Antithrombotic Trialists’ Collaboration. Collaborative meta–analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. [Erratum in: BMJ 2002;324:141]. BMJ. 2002;324:71–86
  7. Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use (An update). Stroke. 2005;36:1801–1807
  8. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease (A systematic review). JAMA. 2007;297:2018–2024
  9. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, et al. Aspirin response and failure in cerebral infarction. Stroke. 1993;24:345–350
  10. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367:606–617
  11. Szczeklik A, Musial J, Undas A, Sanak M. Aspirin resistance. J Thromb Haemost. 2005;3:1655–1662
  12. Gorelick PB, Richardson D, Kelly M, Ruland S, Hung E, Harris Y, et al. African American Antiplatelet Stroke Prevention Study Investigators Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289:2947–2957
  13. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) (CAPRIE Steering Committee). Lancet. 1996;348:1329–1339
  14. Gorelick PB, Born GV, D’Agostino RB, Hanley DF, Moye L, Pepine CJ. Therapeutic benefit (Aspirin revisited in light of the introduction of clopidogrel). Stroke. 1999;30:1716–1721
  15. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. MATCH investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high–risk patients (MATCH): randomized, double–blind, placebo–controlled trial. Lancet. 2004;364:331–337
  16. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717
  17. Gorelick PB, Sechenova O, Hennekens CH. Evolving perspectives on clopidogrel in the treatment of ischemic stroke. J Cardiovasc Pharmacol Ther. 2006;11:245–248
  18. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2 (Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke). J Neurol Sci. 1996;143:1–13
  19. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPIRIT): randomized controlled trial. [Erratum in: Lancet 2007;369:274] Lancet. 2006;367:1665–1673
  20. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. American Heart Association/American Stroke Association Stroke Council Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group Cardiovascular Nursing Council Clinical Cardiology Council Nutrition, Physical Activity, and Metabolism Council Quality of Care and Outcomes Research Interdisciplinary Working Group American Academy of Neurology Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. [Erratum in: Stroke 2007;38:207]. Stroke. 2006;37:1583–1633
  21. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Expert Panel/Writing Group American Heart Association American Academy of Family Physicians American College of Obstetricians and Gynecologists American College of Cardiology Foundation Society of Thoracic Surgeons American Medical Women’s Association Centers for Disease Control and Prevention Office of Research on Women’s Health Association of Black Cardiologists American College of Physicians World Heart Federation National Heart, Lung, and Blood Institute American College of Nurse Practitioners Evidence–based guidelines for cardiovascular disease prevention in women: 2007 update. [Erratum in: Circulation 2007;115:e407]. Circulation. 2007;115:1481–1501
  22. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. American Heart Association American Diabetes Association Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114–126
  23. Gorelick PB. Combining aspirin with oral anticoagulant therapy (Is this a safe and effective practice in patients with atrial fibrillation?). Stroke. 2007;38:1–2

PII: S1933-1711(07)00163-5

doi: 10.1016/j.jash.2007.07.003

Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 3-7 , January 2008

Article Tools